Monoclonal gammopathies of undetermined significance

R. A. Kyle, S Vincent Rajkumar

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Monoclonal gammopathy of undetermined significance is characterized by a serum M-protein level less than 3 g/dL, fewer than 10% plasma cells in the bone marrow, and no or only small amounts of M-protein in the urine; by the absence of lytic lesions, anemia, hypercalcemia, and renal insufficiency; and most importantly, by the stability of the M-protein and by the failure of other abnormalities to develop. Monoclonal gammopathy of undetermined significance is found in approximately 3% of persons older than 70 years and in 1% of those older than 50 years. Approximately one fourth of patients develop MM, AL, WM, or a similar malignant lymphoproliferative disorder during long-term follow-up. In a series of 241 patients at the Mayo Clinic, the actuarial rate of development of serious disease was 16% at 10 years and 40% at 25 years. The median interval from recognition of the M-protein to the diagnosis of MM was 10 years (range, 2-29 years). The plasma cell labeling index and the presence of circulating plasma cells in the peripheral blood suggest active disease. There are no findings at the time of recognition of MGUS that distinguish patients who will remain stable from those in whom a malignant plasma cell proliferative disorder will develop. Therefore, one must perform serial measurements of the M-protein and periodically evaluate the clinical and laboratory features.

Original languageEnglish (US)
Pages (from-to)1181-1202
Number of pages22
JournalHematology/Oncology Clinics of North America
Volume13
Issue number6
StatePublished - 1999

Fingerprint

Monoclonal Gammopathy of Undetermined Significance
Plasma Cells
Proteins
Lymphoproliferative Disorders
Protein Stability
Hypercalcemia
Renal Insufficiency
Anemia
Blood Proteins
Bone Marrow
Urine

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Monoclonal gammopathies of undetermined significance. / Kyle, R. A.; Rajkumar, S Vincent.

In: Hematology/Oncology Clinics of North America, Vol. 13, No. 6, 1999, p. 1181-1202.

Research output: Contribution to journalArticle

@article{3f37519bdcbf49a39bcfbbcf0167e4c7,
title = "Monoclonal gammopathies of undetermined significance",
abstract = "Monoclonal gammopathy of undetermined significance is characterized by a serum M-protein level less than 3 g/dL, fewer than 10{\%} plasma cells in the bone marrow, and no or only small amounts of M-protein in the urine; by the absence of lytic lesions, anemia, hypercalcemia, and renal insufficiency; and most importantly, by the stability of the M-protein and by the failure of other abnormalities to develop. Monoclonal gammopathy of undetermined significance is found in approximately 3{\%} of persons older than 70 years and in 1{\%} of those older than 50 years. Approximately one fourth of patients develop MM, AL, WM, or a similar malignant lymphoproliferative disorder during long-term follow-up. In a series of 241 patients at the Mayo Clinic, the actuarial rate of development of serious disease was 16{\%} at 10 years and 40{\%} at 25 years. The median interval from recognition of the M-protein to the diagnosis of MM was 10 years (range, 2-29 years). The plasma cell labeling index and the presence of circulating plasma cells in the peripheral blood suggest active disease. There are no findings at the time of recognition of MGUS that distinguish patients who will remain stable from those in whom a malignant plasma cell proliferative disorder will develop. Therefore, one must perform serial measurements of the M-protein and periodically evaluate the clinical and laboratory features.",
author = "Kyle, {R. A.} and Rajkumar, {S Vincent}",
year = "1999",
language = "English (US)",
volume = "13",
pages = "1181--1202",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Monoclonal gammopathies of undetermined significance

AU - Kyle, R. A.

AU - Rajkumar, S Vincent

PY - 1999

Y1 - 1999

N2 - Monoclonal gammopathy of undetermined significance is characterized by a serum M-protein level less than 3 g/dL, fewer than 10% plasma cells in the bone marrow, and no or only small amounts of M-protein in the urine; by the absence of lytic lesions, anemia, hypercalcemia, and renal insufficiency; and most importantly, by the stability of the M-protein and by the failure of other abnormalities to develop. Monoclonal gammopathy of undetermined significance is found in approximately 3% of persons older than 70 years and in 1% of those older than 50 years. Approximately one fourth of patients develop MM, AL, WM, or a similar malignant lymphoproliferative disorder during long-term follow-up. In a series of 241 patients at the Mayo Clinic, the actuarial rate of development of serious disease was 16% at 10 years and 40% at 25 years. The median interval from recognition of the M-protein to the diagnosis of MM was 10 years (range, 2-29 years). The plasma cell labeling index and the presence of circulating plasma cells in the peripheral blood suggest active disease. There are no findings at the time of recognition of MGUS that distinguish patients who will remain stable from those in whom a malignant plasma cell proliferative disorder will develop. Therefore, one must perform serial measurements of the M-protein and periodically evaluate the clinical and laboratory features.

AB - Monoclonal gammopathy of undetermined significance is characterized by a serum M-protein level less than 3 g/dL, fewer than 10% plasma cells in the bone marrow, and no or only small amounts of M-protein in the urine; by the absence of lytic lesions, anemia, hypercalcemia, and renal insufficiency; and most importantly, by the stability of the M-protein and by the failure of other abnormalities to develop. Monoclonal gammopathy of undetermined significance is found in approximately 3% of persons older than 70 years and in 1% of those older than 50 years. Approximately one fourth of patients develop MM, AL, WM, or a similar malignant lymphoproliferative disorder during long-term follow-up. In a series of 241 patients at the Mayo Clinic, the actuarial rate of development of serious disease was 16% at 10 years and 40% at 25 years. The median interval from recognition of the M-protein to the diagnosis of MM was 10 years (range, 2-29 years). The plasma cell labeling index and the presence of circulating plasma cells in the peripheral blood suggest active disease. There are no findings at the time of recognition of MGUS that distinguish patients who will remain stable from those in whom a malignant plasma cell proliferative disorder will develop. Therefore, one must perform serial measurements of the M-protein and periodically evaluate the clinical and laboratory features.

UR - http://www.scopus.com/inward/record.url?scp=0033371853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033371853&partnerID=8YFLogxK

M3 - Article

C2 - 10626144

AN - SCOPUS:0033371853

VL - 13

SP - 1181

EP - 1202

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 6

ER -